medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2015, Number 4

<< Back Next >>

Rev Invest Clin 2015; 67 (4)

Proton Magnetic Resonance Spectroscopy Changes in Parkinson’s Disease With and Without Psychosis

Rodríguez-Violante M, Cervantes-Arriaga A, González-Latapí P, León-Ortiz P, de la Fuente-Sandoval C, Corona T

Language: English
References: 45
Page: 227-234
PDF size: 215.42 Kb.


ABSTRACT

Background: Psychosis prevalence in Parkinson’s disease is estimated at 8-30%. Proton magnetic resonance spectroscopy measures specific metabolites as markers of cell functioning. Objective: To study N-acetyl-aspartate and glutamate levels in the caudate and putamen nuclei in subjects with Parkinson’s disease with and without psychosis. Methods: We included 20 nondemented Parkinson’s disease patients with psychosis and 20 Parkinson’s disease patients without psychosis matched for age, sex, disease duration, and levodopa equivalent daily dose, all attended at an academic medical center. Proton magnetic resonance spectroscopy scans were performed in a 3T GE whole-body scanner. Results: Decreased glutamate levels scaled to creatine were found in the dorsal caudate (p = 0.005) and putamen (p = 0.007) of the Parkinson’s disease psychosis group compared with the without psychosis group. Glutamate plus glutamine levels scaled to creatine and N-acetyl-aspartate levels scaled to creatine were also significantly reduced in the dorsal caudate of the Parkinson’s disease with psychosis group (p = 0.018 and p = 0.011, respectively). No group differences were found for any of the other metabolites in the two regions of interest. Conclusions: Our findings suggest that decreased metabolite levels in specific brain areas may be implicated in the development of psychosis in Parkinson’s disease.


REFERENCES

  1. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: A population-based, prospective study. J Am Geriatr Soc. 2000;48:938-42.

  2. Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson’s disease: A review. Drugs Aging. 2008;25:665-82.

  3. Mack J, Rabins P, Anderson K, et al. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry. 2012;20:123-32.

  4. Armstrong RA. Visual symptoms in Parkinson’s disease. Parkinsons Dis. 2011:908306.

  5. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson’s disease as disturbed external/internal perceptions: Focused review and a new integrative model. Mov Disord. 2005;20:130-40.

  6. Maddock RJ, Buonocore MH. MR spectroscopic studies of the brain in psychiatric disorders. Curr Top Behav Neurosci. 2012; 11:199-251.

  7. Zheng XN, Zhu XC, Ruan LX, et al. MRS study on lentiform nucleus in idiopathic Parkinson’s disease with unilateral symptoms. J Zhejiang Univ Sci. 2004;5:246-50.

  8. Griffith HR, Okonkwo OC, O’Brien T, Hollander JA. Reduced brain glutamate in patients with Parkinson’s disease. NMR Biomed. 2008;21:381-7.

  9. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:745-52.

  10. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: Report of an NINDS, NIMH work group. Mov Disord. 2007;22:1061-8.

  11. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25:2649-53.

  12. Fahn S, Elton RL. UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson’s Disease, Vol. 2. Florham Park, NJ: Macmillan Health Care Information 1987; 153-63, 293-304.

  13. Kay SR, Opler LA, Lindenmayer JP. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13:261-76.

  14. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001;14:260-4.

  15. Collerton D, Taylor JP. Advances in the treatment of visual hallucinations in neurodegenerative diseases. Future Neurol. 2013;8:433-44.

  16. Lenka A, Jhunjhunwala KR, Saini J, Pal PK. Structural and functional neuroimaging in patients with Parkinson’s disease and visual hallucinations: A critical review. Parkinsonism Relat Disord; 2015;21:683-91.

  17. Pagonabarraga J, Soriano-Mas C, Llebaria G, López-Solá M, Pujol J, Kulisevsky J. Neural correlates of minor hallucinations in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:290-6.

  18. Kiferle L, Ceravolo R, Giuntini M, et al. Caudate dopaminergic denervation and visual hallucinations: evidence from a 123I-FPCIT SPECT study. Parkinsonism Relat Disord. 2014;20:761-5.

  19. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology. 2004;63:1409-16.

  20. Martinez D, Slifstein M, Broft A, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab. 2003;23:285-300.

  21. Redgrave P, Prescott TJ, Gurney K. The basal ganglia: a vertebrate solution to the selection problem? Neuroscience. 1999; 89:1009-23.

  22. Agarwal N, Renshaw PF. Proton MR spectroscopy-detectable major neurotransmitters of the brain: biology and possible clinical applications. AJNR Am J Neuroradiol. 2012;33:595-602.

  23. Salter BC, Anderson KE, Weiner WJ. Psychosis in Parkinson’s disease: Case studies. Neurol Clin. 2006;24:363-9.

  24. Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa in hallucinating Parkinson’s disease patients: High-dose challenge does not precipitate hallucinations. Neurology. 1998;50:515-17.

  25. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson’s disease: A community-based study. Arch Neurol. 1999;56:595-601.

  26. Fénelon G, Goetz, CG, Karenberg A. Hallucinations in Parkinson’s disease in the prelevodopa era. Neurology. 2006;66:93-8.

  27. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2001;70:734-8.

  28. Clarke CE, Lowry M. Basal ganglia metabolite concentrations in idiopathic Parkinson’s disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur J Neurol. 2000;7:661-5.

  29. Taylor-Robinson SD, Turjanski N, Bhattacharya S, et al. A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson’s disease. Metab Brain Dis. 1999;14:45-55.

  30. Clarke CE, Lowry M, Horsman A. Unchanged basal ganglia Nacetylaspartate and glutamate in idiopathic Parkinson’s disease measured by proton magnetic resonance spectroscopy. Mov Disord. 1997;12:297-301.

  31. Kickler N, Krack P, Fraix V, et al. Glutamate measurement in Parkinson’s disease using MRS at 3 T field strength. NMR Biomed. 2007;20:757-62.

  32. Cepeda C, Levine MS. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev Neurosci. 1998;20:1-18.

  33. West AR, Floresco SB, Charara A, Rosenkranz JA, Grace AA. Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann N Y Acad Sci. 2003;1003:53-74.

  34. David HN, Ansseau M, Abraini JH. Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate- putamen and nucleus accumbens of “intact” animals. Brain Res Rev. 2005;50:336-60.

  35. Morales I, Fuentes A, Ballaz S, Obeso JA, Rodriguez M. Striatal interaction among dopamine, glutamate and ascorbate. Neuropharmacology. 2012;63:1308-14.

  36. Meoni P, Bunnemann BH, Kingsbury AE, Trist DG, Bowery NG. NMDA NR1 subunit mRNA and glutamate NMDA-sensitive binding are differentially affected in the striatum and pre-frontal cortex of Parkinson’s disease patients. Neuropharmacology. 1999;38:625-33.

  37. Barker PB. N-acetyl aspartate--a neuronal marker? Ann Neurol. 200149:423-4.

  38. Taylor MJ, Godlewska BR, Norbury R, Selvaraj S, Near J, Cowen PJ. Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate. Int J Neuropsychopharmacol. 2012;15:1541-6.

  39. Bowen BC, Block RE, Sanchez-Ramos J, et al. Proton MR spectroscopy of the brain in 14 patients with Parkinson’s disease. AJNR Am J Neuroradiol. 1995;16:61-8.

  40. Camicioli RM, Hanstock CC, Bouchard TP, Gee M, Fisher NJ, Martin WR. Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson’s disease. Mov Disord. 2007;22:382-6.

  41. Holshouser BA, Komu M, Möller HE, et al. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson’s disease: A multicenter pilot study. Magn Reson Med. 1995;33:589-94.

  42. Zhou B, Yuan F, He Z, Tan C. Application of proton magnetic resonance spectroscopy on substantia nigra metabolites in Parkinson’s disease. Brain Imaging Behav. 2014;8:97-101.

  43. Lucetti C, Del Dotto P, Gambaccini G, et al. Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson’s disease patients. Neurol Sci. 2001;22:69-70.

  44. Camicioli RM, Korzan JR, Foster SL, et al. Posterior cingulate metabolic changes occur in Parkinson’s disease patients without dementia. Neurosci Lett. 2004;354:177-80.

  45. Nie K, Zhang Y, Huang B, et al. Marked N-acetylaspartate and choline metabolite changes in Parkinson’s disease patients with mild cognitive impairment. Parkinsonism Relat Disord. 2013;19:329-34.




2020     |     www.medigraphic.com